Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
NCT ID: NCT05876130
Last Updated: 2024-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
92 participants
INTERVENTIONAL
2022-11-01
2031-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
NCT06509724
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
NCT05857631
A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients
NCT00373620
Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
NCT04956601
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer
NCT04453904
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
POHIM_EM
adjuvant hypofractionated IMRT for endometrial cancer
POHIM_EM
hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
POHIM_EM
hypofractionated intensity-modulated radiation therapy (2.5 Gy/fraction, 16 fractions)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* completion of hysterectomy and surgical staging
* pathologically confirmed FIGO stage III
* ECOG performance status 0 or 1
* adjuvant chemotherapy was done or planned
Exclusion Criteria
* previous history of pelvic radiotherapy
* severe and unstable medical condition
* previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer
20 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Won Park
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Won Park
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-09-123
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.